Quote:

---

Non-imaging biomarkers, including molecules measured in the blood, urine, cerebrospinal fluid, or other parts of the body may also prove to be useful tools in the diagnosis and monitoring of Alzheimer’s. For example, researchers are focusing on biomarkers that indicate the level of betaamyloid in the brain, and those indicating that neurons are either damaged or deteriorating.

Researchers believe that biomarkers will eventually be critical for identifying individuals with early stage Alzheimer’s and monitoring the effects of treatment.33 As our ability to reliably diagnose the disease grows so does our ability to develop effective treatments.

---